LON:ABZA - Abzena Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
GBX 15.75 0.00 (0.00 %)
(As of 10/16/2018 04:00 PM ET)
Previous CloseGBX 15.75
Today's RangeGBX 15.75 - GBX 15.75
52-Week RangeGBX 24.50 - GBX 53
VolumeN/A
Average Volume26,706 shs
Market Capitalization£50.91 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Abzena plc provides services and technologies for the selection, development, and manufacture of biopharmaceutical products in North America, Europe, and internationally. Its technologies include antibody drug conjugate (ADC) linker, antibody humanization, and protein deimmunisation. It provides phage display, Hybridoma sequencing, and developability assessment solutions for the discovery, isolation, development, and selection of antibodies; immunogenicity assessment and custom assays, as well as Cytokine Screen, an in vitro assay to evaluate the risk of biopharmaceutical products causing cytokine storm prior to it being progressed into clinical development. It also offers antibody and protein engineering solutions, which cover Ig class and isotype switching, antibody reformatting and humanization, protein deimmunisation, affinity maturation, antibody and protein production, and bioassays and bioanalytics; and ADCs, such as cysteine and lysine conjugation solutions, as well as ThioBridge, a disulfide rebridging conjugation technology. In addition, it provides solutions in the area of bioassays, which cover drug-conjugate and payload characterization, binding and competition assays, cell health assays, functional assays, Fc binding and function assays, and bespoke assay development; bioanalytics that cover candidate selection, biosimilarity, protein and peptide identification, ADC characterization, and analytical method development; peptide synthesis, modifications, and analytics; mammalian manufacturing, which cover cell line, process, and analytical development, as well as cell banking; peptide synthesis, modifications, and analytics; bioconjugates and ADCs manufacturing; and custom, library, HPAPI, and payload synthesis. Further, it offers full-time equivalent and protein/BioNMR services; and analytical solutions. It serves biopharmaceutical companies and academic groups. Abzena plc was incorporated in 2014 and is headquartered in Cambridge, the United Kingdom.

Receive ABZA News and Ratings via Email

Sign-up to receive the latest news and ratings for ABZA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange LON
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
SymbolLON:ABZA
CUSIPN/A
Phone+44-1223-903498

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-83.31%
Return on Equity-36.99%
Return on Assets-30.72%

Miscellaneous

EmployeesN/A
Outstanding Shares213,820,000
Market Cap£50.91 million

Abzena (LON:ABZA) Frequently Asked Questions

What is Abzena's stock symbol?

Abzena trades on the London Stock Exchange (LON) under the ticker symbol "ABZA."

What price target have analysts set for ABZA?

4 analysts have issued 1 year price objectives for Abzena's stock. Their forecasts range from GBX 40 to GBX 70. On average, they expect Abzena's share price to reach GBX 53 in the next year. This suggests a possible upside of 236.5% from the stock's current price. View Analyst Price Targets for Abzena.

What is the consensus analysts' recommendation for Abzena?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Abzena in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Abzena.

Who are some of Abzena's key competitors?

Who are Abzena's key executives?

Abzena's management team includes the folowing people:
  • Dr. William John Edward Burt, CEO & Exec. Director (Age 50)
  • Prof. Sunil Shaunak, Co-Founder & Chairman of the Scientific Advisory Board
  • Dr. Antony Godwin Ph.D., Co-Founder
  • Prof. Steve Brocchini Ph.D., Co-Founder
  • Mr. John Brian Hansen Johnson, Interim Chief Operating Officer (Age 57)

How do I buy shares of Abzena?

Shares of ABZA and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Abzena's stock price today?

One share of ABZA stock can currently be purchased for approximately GBX 15.75.

How big of a company is Abzena?

Abzena has a market capitalization of £50.91 million.

What is Abzena's official website?

The official website for Abzena is http://www.abzena.com/.

How can I contact Abzena?

Abzena's mailing address is Babraham Hall, Babraham Research, CAMBRIDGE, CB22 3AT, United Kingdom. The company can be reached via phone at +44-1223-903498.


MarketBeat Community Rating for Abzena (LON ABZA)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  167 (Vote Outperform)
Underperform Votes:  103 (Vote Underperform)
Total Votes:  270
MarketBeat's community ratings are surveys of what our community members think about Abzena and other stocks. Vote "Outperform" if you believe ABZA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ABZA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/16/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel